Tackling the critical unanswered questions in cancer immunotherapy research

2020 Annual Report
Following a decade of astonishing progress, immunotherapy has emerged as a major breakthrough in cancer treatment—accelerating scientific research, changing cancer care, and saving lives. Turning these advances into potential cures for all cancer patients, however, requires that we focus our efforts on exploring the critical, unanswered questions in the field. In 2020, we made significant strides toward deepening our understanding of these questions, which we describe in this year's annual report. Little did we know, however, that the field, and the world, would be shaken by a new crisis.

While cancer continues to be a leading cause of death worldwide, a new menace emerged this January: the SARS-CoV-2 virus and COVID-19 pandemic. Working at the intersection of immunology and cancer biology, CRI scientists rose to join the fight. Our organization adjusted to the health crisis to protect our staff, supporters, and the communities we serve. Moreover, donor generosity made it possible for us to provide an unprecedented “lifeline” funding extension to 23 postdoctoral fellows.

Despite the challenges, we have not lost sight of our mission to save more lives by fueling the discovery and development of powerful immunotherapies for all cancers. We continue to tackle the profound and unanswered questions in cancer research with the support of our generous donors. We remain focused on: A Future Immune to Cancer.

OUR MISSION: SAVE MORE LIVES by fueling the discovery and development of powerful immunotherapies for all cancers.

Founded in 1953, the Cancer Research Institute (CRI) is a 501(c)(3) nonprofit organization dedicated to funding laboratory and clinical research aimed at harnessing our immune system’s power to treat and potentially cure all cancers. This work has led to a revolutionary new class of cancer treatments called immunotherapy, which today is giving millions of cancer patients a better chance at living longer.
Why do some people respond to immunotherapy but not others?

Over the past decade, cancer immunotherapy has transformed our ability to treat more than twenty types of advanced cancer. The immune system’s power may enable us in the near future to conquer all forms of the disease, but first we must improve our understanding of how it works in the context of cancer—down to the molecular level. Ansuman Satpathy, M.D., Ph.D., Sumit K. Subudhi, M.D., Ph.D., Padmanee Sharma, M.D., Ph.D., James P. Allison, Ph.D., and Yunlong Zhao, Ph.D., are just a few of the CRI scientists applying the latest discoveries and new technologies to expand the benefits of immunotherapy to more cancer patients.

What immune cells besides T cells can we effectively unleash to fight cancer?

Much of the recent success in cancer immunotherapy can be tied back to one immune cell: the T cell. However, there are many more cells in the immune system, each with great potential to help patients. B cells release antibodies to defend against threats in the body. Dendritic cells help orchestrate immune responses against threats including cancer. Macrophages engulf and destroy bacteria, virus-infected cells, and cancer as well as present antigens to other immune cells. Natural killer cells are part of our innate immune system’s defense against cancer and pathogens, patrolling the body and acting as first responders. Oscar A. Aguilar, Ph.D., Pranay Dogra, Ph.D., Martina Molgora, Ph.D., Timothy Fessenden, Ph.D., Cheng-Sheng Lee, Ph.D., and Zhaoqing Ba, Ph.D., are just a few of the CRI scientists examining these extraordinary immune cells and their untapped potential in cancer immunotherapy.

Can we accelerate discovery and development through smarter clinical trial design?

Clinical trials are an essential step toward giving patients more treatment options, but they can take many years to implement and complete—time many cancer patients don’t have. The CRI Anna-Maria Kellen Clinical Accelerator has developed a way to overcome these barriers to clinical development: platform trials. Rather than test new drugs or drug combinations in sequence, we can test them simultaneously and allow for mid-course corrections—getting effective treatments to patients faster.

Of course, these clinical trials could not happen without the participation of courageous patients not only seeking the best treatments for themselves, but also willing to contribute to medical research responsible for future breakthroughs. The CRI Answer to Cancer Patient Education Program reached thousands, if not millions, of cancer patients through a variety of educational programs and initiatives in the past year, and continues to connect many to immunotherapy clinical trials for which they may be eligible.
The Cancer Research Institute funds the entire spectrum of scientific discovery, from basic laboratory studies on the fundamentals of the immune system to clinical trials of cutting-edge immunotherapy combinations. CRI’s funding decisions are guided by a renowned Scientific Advisory Council that includes four Nobel Laureates and 26 members of the National Academy of Sciences. In Fiscal Year 2020, CRI awarded $30.2 million in grants and fellowships to scientists around the world.

### Grants and Awards

<table>
<thead>
<tr>
<th>Program</th>
<th>Amount</th>
<th>Scientists Awarded</th>
</tr>
</thead>
<tbody>
<tr>
<td>CRI Irvington Postdoctoral Fellowship Program</td>
<td>$6,311,750</td>
<td>32</td>
</tr>
<tr>
<td>CRI Irvington Postdoctoral Fellowship Program</td>
<td>$6,311,750</td>
<td>32</td>
</tr>
<tr>
<td>CRI Irvington Postdoctoral Fellowship Program</td>
<td>$6,311,750</td>
<td>32</td>
</tr>
<tr>
<td>Clinic and Laboratory Integration Program (CLIP)</td>
<td>$2,391,600</td>
<td>12</td>
</tr>
<tr>
<td>Clinic and Laboratory Integration Program (CLIP)</td>
<td>$2,391,600</td>
<td>12</td>
</tr>
<tr>
<td>CRI Anna-Maria Kellen Clinical Accelerator</td>
<td>$12,567,893</td>
<td>8</td>
</tr>
<tr>
<td>CRI Anna-Maria Kellen Clinical Accelerator</td>
<td>$12,567,893</td>
<td>8</td>
</tr>
<tr>
<td>Lloyd J. Old STAR Awards</td>
<td>$6,250,000</td>
<td>5</td>
</tr>
<tr>
<td>Technology Impact Awards</td>
<td>$1,000,000</td>
<td>5</td>
</tr>
<tr>
<td>Technology Impact Awards</td>
<td>$1,000,000</td>
<td>5</td>
</tr>
<tr>
<td>Impact Grants</td>
<td>$1,642,560</td>
<td>2</td>
</tr>
<tr>
<td>Impact Grants</td>
<td>$1,642,560</td>
<td>2</td>
</tr>
</tbody>
</table>

---

Read the full report at cancerresearch.org/impact
Our work to advance lifesaving science is possible only with the generous support of individual donors, philanthropic foundations, and corporate sponsors who share our vision of A Future Immune to Cancer™. In Fiscal Year 2020, donors and supporters gave or raised more than $31.6 million for the Cancer Research Institute.
Donor trust is our most valued asset. We earn and keep this trust through our commitment to accountability and transparency, holding ourselves to the highest standards of fiscal integrity and responsible use of donor dollars to achieve the greatest mission impact.

**Total Support and Revenues**

- **CONTRIBUTIONS**
  - $28.6 million
  - 73%
- **BEQUESTS AND MEMORIALS**
  - $5.8 million
  - 15%
- **INVESTMENTS AND OTHER**
  - $3.2 million
  - 8%
- **SPECIAL EVENTS**
  - $1.6 million
  - 4%

**Total Support and Revenues**

$39.1M

**End of Year Net Assets**

$60.3 million

**Financial Highlights**

- **RESEARCH**
  - $24.1 million*
- **SCIENCE, MEDICAL, AND RESEARCH INFORMATION AND COMMUNICATIONS**
  - $3.9 million
- **MARKETING AND DEVELOPMENT**
  - $2.8 million
- **ADMINISTRATION**
  - $1.6 million
- **ALLOWANCE FOR UNCOLLECTIBLE ACCOUNTS**
  - $3.4 million

* $30.2 million awarded minus $6.1 million in early terminations of grants and clinical trials from prior years
Leaders in business, philanthropy, and science volunteer their time and expertise to guide the Cancer Research Institute's strategic course, oversee its operations, shape its mission-driven programs, and increase awareness of CRI's impact.

BOARDS OF TRUSTEES

Co-Chairmen
Paul C. Shiverick
Andrew K. Tsai

Vice Chairmen
Edgar R. Berner
John B. Fitzgibbon
Donald J. Gogel
Jacques C. Nordeman
Andrew M. Paul

Treasurer
Geoffrey O. Coley

Secretary
Thomas G. Mendell

Members
Tony C. Alvarez II
Yacov Arnopolin
Kamini Banga
Peter L. Bloom
Brian Brille
W. Robert Dahl
Glenn J. DeSimone
Sean P. Fahey
Margot E. Freedman
Oliver R. Grace Jr.
Sandra Coudert Graham
Michael M. Kellen
Mirra Lohrasbpour
Alexander P. Lynch
Dana Maiman
Michael J. Petrick
Lief D. Rosenblatt
Frank V. Sica
James A. Stern
Robert S. Stolar
Michael B. Targoff
Diane Tuft
Heidi J. Ueberroth
Lauren S. Veronis
Ronald G. Weiner
Jim Weiss
Peter Zhou

ASSOCIATE BOARD

Chairman
Trent Kososki

Members
Michael Arias
Javier Artola
Adler Bernard
Michael Brown
Ross Bruck
Rada Cevher
Morgan Cheatham
Robert W. Chen
Eash Cumarasamy
Lauren Edelson
Isabelle Franks
Andrew Goldman
Matt Goldman
Jack Griffin
Tj Gupta
Courtney Shields Hassen
Tyler Hassen
Brooke James
Patrick King
Sam Shiverick
Muhammad Siddiqui
Christina S. Leslie, Ph.D.
Michael Kalos, Ph.D.
Dan R. Littman, M.D., Ph.D.
Nils Lonberg, Ph.D.
Tak W. Mak, Ph.D., D.S.C., FRSC
Philippa C. Marrack, Ph.D.
Malcolm A.S. Moore, D.Phil. (Ret.)
Lee Nadler, M.D.
Drew M. Pardoll, M.D., Ph.D.
Klaus Rajewsky, M.D.

STAFF

Jill O'Donnell-Tormey, Ph.D.
Chief Executive Officer and Director of Scientific Affairs

Brian M. Brewer
Director of Marketing and Communications

Jay Campbell
Managing Director of CRI Clinical Accelerator and Venture Fund

 Lynne A. Harmer
Director of Grants Administration and Special Events

Rupinder Kaur
Director of Data Systems and Operations

Alfred R. Massidas
Chief Financial Officer and Director of Human Resources

Deanne Marbach
Director of Major Gifts

Sharon Slade
Director of Strategic Initiatives

Arthur N. Brodsky, Ph.D.
Janet Fernandez
Kelly Flynn
Ryan Godfrey
Cierra Howard
Rachel Jones
Maria S. Lawson
Robert Levine, MBA
Jasmine Lingard
Shasell Negron
Alice Northover
Caroline Offit
Lillian Ramos
Kajol Sankar
Chary Sathea
Alexa Schles
Natasha Shah
Devi Sharma
Samik Upadhyaya, Ph.D.
Jia Xin Yu, Ph.D.
Qing Hua Zhang

Governance and Guidance

Read the full report at cancerresearch.org/impact